ArticleScientific reports2026
GOLGB1 deficiency accelerates intervertebral disc degeneration by activating the MAPK pathway.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Intervertebral disc degeneration (IDD) is a multifactorially regulated age-related condition. Golgin B1 (GOLGB1) is a large Golgi-related transmembrane protein encoded by golgb1 gene. Since its discovery, GOLGB1 has been proved to be related to many diseases. However, its role in IDD is still unclear. The aim of this research was to examine whether GOLGB1 deficiency accelerates disc degeneration and to study its mechanism. We selected C57BL/6 male mice aged 8 weeks to isolate, culture and identify nucleus pulposus (NP) cells, and used a variety of experimental techniques, including plasmid transfection, western blotting (WB), real-time fluorescence quantitative PCR (RT-qPCR), EdU staining, Tunnel staining, CCK8 and flow cytometry (FCM) to detect the effects of GOLGB1 on the degeneration, proliferation and apoptosis of NP cells in vitro. Then, 8-week-old C57BL/6 male mice were selected for caudal vertebra acupuncture to establish IDD model, and the role and mechanism of GOLGB1 in the development of IDD were studied by HE staining, Safranin O-Fast Green staining, Alcian Blue staining and immunohistochemistry (IHC) staining. Our results demonstrated lower expression of GOLGB1 in human tissues with NP degeneration. Additionally, GOLGB1 expression was reduced in NP tissue from aging adult mice and IDD model mice. We further verified that GOLGB1 knockdown worsened NP cell degeneration, disturbed the composition of the extracellular matrix (ECM), and upset the harmony between anabolism and catabolism. Moreover, GOLGB1 knockdown inhibited the proliferation of NP cells and increased the apoptosis of NP cells. Mechanistically, GOLGB1 knockdown elevated p-ERK and p-P38 levels and activated the MAPK pathway. A MAPK signaling pathway inhibitor (SCH772984) strongly reversed this phenomenon and rescued the degeneration of NP cells. These findings suggest that GOLGB1 may be a potential new target for IDD. GOLGB1 is a protective factor against disc degeneration, and knockdown of GOLGB1 accelerates IDD by activating the MAPK pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.